Abstract
(Molecular Therapy 29, 1808–1820; May 5,2021) In the originally published version of this article, a reference to Figure 2 was incorrect in the text, and the Figure 3 legend description was reversed for Figures 3E and 3F. The y-axis in Figure 3E was represented as a percentage rather than a fraction. The data remain unchanged. The figure and legend have now been corrected online. The authors regret this error.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3529-3533 |
| Number of pages | 5 |
| Journal | Molecular Therapy |
| Volume | 29 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2021 |
ASJC Scopus subject areas
- Molecular Medicine
- Molecular Biology
- Genetics
- Pharmacology
- Drug Discovery
Fingerprint
Dive into the research topics of 'Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity (Molecular Therapy (2021) 29(5) (1808–1820), (S152500162100071X), (10.1016/j.ymthe.2021.02.004))'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS